Drugs which either directly or indirectly stimulate hypothalamic 5-HT2C receptors in rodents produce both changes in the structure of feeding behavior and reductions in food intake that are consistent with the satiety process. These drugs cause an enhancement of the postmeal satiety potency of fixed caloric loads and reduce premeal appetite and food intake at ad libitum meals in both lean and obese humans. 5-HT drugs also produce sustained reductions in body weight gain in rodents, effects that mirror the weight loss-inducing effects of fenfluramine, d-fenfluramine, and sibutramine in humans. Antiobesity treatments have and will continue to target the endogenous 5-HT satiety system. A new generation of selective 5-HT2C agonists have been developed and some have passed into clinical testing. The selectivity of these compounds should ensure that they avoid the negative side effects associated with their predecessors. Currently, the effects on appetite expression of 5-HT drugs currently under development remain at least unpublished if not completely unknown. However, results are imminent. To conclude, it is over 40 years since Blundell linked the effects of 5-HT drugs on rodent feeding behavior with satiety. Despite the intervening years, and the identification of many other systems critical to energy regulation, endogenous 5-HT remains central to our understanding of human appetite expression.

Defeat Drugs and Live Free

Defeat Drugs and Live Free

Being addicted to drugs is a complicated matter condition that's been specified as a disorder that evidences in the obsessional thinking about and utilization of drugs. It's a matter that might continue to get worse and become disastrous and deadly if left untreated.

Get My Free Ebook

Post a comment